Dr. Rana McKay

Now, I think, you know, certainly if I have somebody before me who's got an extensive cardiac history and they really need to be on ADT, they've got high risk disease and you're treating them with a curative intent and they need to start treatment. Like, yeah, in that context, I'm going to go ahead and prescribe medication.

an antagonist, you know, every day over an agonist just to do everything that I possibly can to mitigate their cardiovascular risk, like whether it be a thrombotic event or arrhythmia or something. So, you know, I think at the end of the day, I think there's probably a little bit more hype than true data. And I think the data that is out there has some flaws in it.

an antagonist, you know, every day over an agonist just to do everything that I possibly can to mitigate their cardiovascular risk, like whether it be a thrombotic event or arrhythmia or something. So, you know, I think at the end of the day, I think there's probably a little bit more hype than true data. And I think the data that is out there has some flaws in it.

an antagonist, you know, every day over an agonist just to do everything that I possibly can to mitigate their cardiovascular risk, like whether it be a thrombotic event or arrhythmia or something. So, you know, I think at the end of the day, I think there's probably a little bit more hype than true data. And I think the data that is out there has some flaws in it.

But I think that, you know, it doesn't necessarily put the person in any worse off situation from an efficacy standpoint or side effects standpoint, and may potentially mitigate some CV tax.

But I think that, you know, it doesn't necessarily put the person in any worse off situation from an efficacy standpoint or side effects standpoint, and may potentially mitigate some CV tax.

But I think that, you know, it doesn't necessarily put the person in any worse off situation from an efficacy standpoint or side effects standpoint, and may potentially mitigate some CV tax.

You know, I do think the antagonists are associated with more rapid time to T recovery. And, you know, I think the other thing that we don't necessarily know is how that potentially plays into their long-term outcomes. You know what I mean?

You know, I do think the antagonists are associated with more rapid time to T recovery. And, you know, I think the other thing that we don't necessarily know is how that potentially plays into their long-term outcomes. You know what I mean?

You know, I do think the antagonists are associated with more rapid time to T recovery. And, you know, I think the other thing that we don't necessarily know is how that potentially plays into their long-term outcomes. You know what I mean?

I don't think there'll ever be a study that'll look at this, but when people, most of the older studies looked at the role with agonists and therapy was that much longer with an agonist as you waited for their T to recover. So does the fact that the T recovers faster, is that gonna impact long-term outcomes? I don't think we really know, but I think it's very much,

I don't think there'll ever be a study that'll look at this, but when people, most of the older studies looked at the role with agonists and therapy was that much longer with an agonist as you waited for their T to recover. So does the fact that the T recovers faster, is that gonna impact long-term outcomes? I don't think we really know, but I think it's very much,

I don't think there'll ever be a study that'll look at this, but when people, most of the older studies looked at the role with agonists and therapy was that much longer with an agonist as you waited for their T to recover. So does the fact that the T recovers faster, is that gonna impact long-term outcomes? I don't think we really know, but I think it's very much,

You kind of want to give patients the duration of the treatment that you want to give them and stop as opposed to having this protracted time that you don't know when they're going to recover. And, you know, so I think it's it's nice to use the antagonist when the course of therapy is finite and you want their T to recover.

You kind of want to give patients the duration of the treatment that you want to give them and stop as opposed to having this protracted time that you don't know when they're going to recover. And, you know, so I think it's it's nice to use the antagonist when the course of therapy is finite and you want their T to recover.

You kind of want to give patients the duration of the treatment that you want to give them and stop as opposed to having this protracted time that you don't know when they're going to recover. And, you know, so I think it's it's nice to use the antagonist when the course of therapy is finite and you want their T to recover.

you know, I think it's slightly different because of the fact that they're going to be on therapy that much longer. You know, I think it's the, you know, muscular loss, the bone loss, metabolic changes can be way more pronounced.

you know, I think it's slightly different because of the fact that they're going to be on therapy that much longer. You know, I think it's the, you know, muscular loss, the bone loss, metabolic changes can be way more pronounced.

you know, I think it's slightly different because of the fact that they're going to be on therapy that much longer. You know, I think it's the, you know, muscular loss, the bone loss, metabolic changes can be way more pronounced.

You know, you have patients, they come into clinic, they're on 24 months of ADT and first visit, they're up two pounds, up two pounds, up two pounds in a year, they've gained 10 pounds and now they've got some, you know, pre-diabetes. And so, you know, The propensity for that to happen with somebody just being on therapy for six months is not as high as, you know, two years of therapy.